Low-dose IL-2 can stimulate the proliferation of Treg cells in the peripheral blood of patients with D2T RA, shift the balance of effector T cells/Treg cells toward Treg cells, restore immune tolerance to a certain extent, and become a new means to improve the immune disorder of RA. This evidence concerns the gene IL2 and immune system disorder.